In vivo fluorescence molecular imaging of the vascular endothelial growth factor in rats with early diabetic retinopathy.
Lu ZhangYunhe DingXinjian ChenDehui XiangFei ShiYanyun ChenShenshen YanXinyuan ZhangZhenyu ZhangSobha SivaprasadYang DuZhi YangBei TianPublished in: Biomedical optics express (2021)
Anti-vascular endothelial growth factor (anti-VEGF) therapy is effective for reducing the severity level of diabetic retinopathy (DR). However, it is difficult to determine the in vivo spatial and temporal expression of VEGF in the DR retina at an early stage. Here, we report a quantitatively fluorescence molecular imaging and image analysis method by creating a VEGF targeted fluorescence imaging probe, which can potentially detect and predict anti-VEGF treatment response. Moreover, the ex vivo multiscale fluorescence imaging demonstrated the spatial correlation between VEGF relative expression and vascular abnormalities in two and three dimensions. It revealed that VEGF was mainly abnormally expressed at the bifurcation of the microvessels, which advances the knowledge of the DR progression by molecular fluorescence imaging. Our study has the potential to achieve early detection of DR disease, provide more insight into understanding anti-VEGF treatment, and may help stratify patients based on the molecular imaging of retinal VEGF.
Keyphrases
- vascular endothelial growth factor
- diabetic retinopathy
- fluorescence imaging
- endothelial cells
- photodynamic therapy
- optical coherence tomography
- early stage
- healthcare
- end stage renal disease
- chronic kidney disease
- stem cells
- editorial comment
- squamous cell carcinoma
- climate change
- single cell
- ejection fraction
- drug delivery
- combination therapy
- human health
- lymph node
- replacement therapy
- long non coding rna
- cell therapy
- living cells
- locally advanced